Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 12/20 | 0.64 |
| ▸ | SRC | P12931 | 3/20 | 0.64 |
| ▸ | GSK3B | P49841 | 2/20 | 0.64 |
| ▸ | AURKA | O14965 | 12/20 | 0.59 |
| ▸ | AURKC | Q9UQB9 | 8/20 | 0.59 |
| ▸ | PLK4 | O00444 | 3/20 | 0.58 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.55 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.55 |
| ▸ | STK25 | O00506 | 1/20 | 0.55 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | GAK | O14976 | 1/20 | 0.55 |
| ▸ | MUSK | O15146 | 1/20 | 0.55 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.55 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086934 | 0.93 | AURKB (0.63) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL1087272 | 0.93 | AURKB (0.66) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL1088559 | 0.92 | AURKB (0.62) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL1101577 | 0.92 | AURKB (0.62) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL1088390 | 0.92 | AURKB (0.61) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL1086941 | 0.90 | AURKB (0.69) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL1087017 | 0.89 | AURKB (0.63) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL1088458 | 0.89 | AURKB (0.68) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL1087829 | 0.89 | AURKB (0.71) | AURKBSRCGSK3BAURKAAURKC | |
| SCHEMBL1088160 | 0.88 | AURKB (0.61) | AURKBSRCGSK3BAURKAAURKC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153630-B2 | of Aurora-2 (Aurora-A) protein kinase; anticancer; 6-(pyrazolylamino)-4-pyrimidine carboxamides; Methyl 2-(4-cyclopropanecarboxamidophenylsulfanyl)-5-amino-6-(5-methylpyrazol-3-ylamino)-4-pyrimidinecarboxylate | MIIKANA THERAPEUTICS, INC. (US) | 2012-04-10 | — | — | US | claimed |
| EP-1812424-A4 | KINASE INHIBITORS | MIIKANA THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20080200485-A1 | Kinase Inhibitors | MIIKANA THERAPEUTICS, INC. | 2008-08-21 | — | — | US | claimed |
| EP-1812424-A2 | KINASE INHIBITORS | Miikana Therapeutics, Inc. (US) | 2007-08-01 | — | — | EP | claimed |
| WO-2006055831-A2 | KINASE INHIBITORS | MIIKANA THERAPEUTICS, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| US-8153630-B2 | of Aurora-2 (Aurora-A) protein kinase; anticancer; 6-(pyrazolylamino)-4-pyrimidine carboxamides; Methyl 2-(4-cyclopropanecarboxamidophenylsulfanyl)-5-amino-6-(5-methylpyrazol-3-ylamino)-4-pyrimidinecarboxylate | MIIKANA THERAPEUTICS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153630-B2 | of Aurora-2 (Aurora-A) protein kinase; anticancer; 6-(pyrazolylamino)-4-pyrimidine carboxamides; Methyl 2-(4-cyclopropanecarboxamidophenylsulfanyl)-5-amino-6-(5-methylpyrazol-3-ylamino)-4-pyrimidinecarboxylate | MIIKANA THERAPEUTICS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153630-B2 | of Aurora-2 (Aurora-A) protein kinase; anticancer; 6-(pyrazolylamino)-4-pyrimidine carboxamides; Methyl 2-(4-cyclopropanecarboxamidophenylsulfanyl)-5-amino-6-(5-methylpyrazol-3-ylamino)-4-pyrimidinecarboxylate | MIIKANA THERAPEUTICS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-1812424-A4 | KINASE INHIBITORS | MIIKANA THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080200485-A1 | Kinase Inhibitors | MIIKANA THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200485-A1 | Kinase Inhibitors | MIIKANA THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200485-A1 | Kinase Inhibitors | MIIKANA THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1812424-A2 | KINASE INHIBITORS | Miikana Therapeutics, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006055831-A2 | KINASE INHIBITORS | MIIKANA THERAPEUTICS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200485-A1 | Kinase Inhibitors | AURKC, AURKA, AURKB | AURKB 3/4885SRC 370/4885GSK3B 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.